

CHEMBIO DIAGNOSTICS, INC.  
Form 8-K  
November 06, 2013  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 6, 2013 (October 31, 2013)

CHEMBIO DIAGNOSTICS, INC.  
(Exact name of registrant as specified in its charter)

|   |   |   |
|---|---|---|
| Nevada<br>(State or other jurisdiction<br>of Incorporation) | 0-30379<br>(Commission File Number)   | 88-0425691<br>(IRS Employer<br>Identification Number) |
|   | 3661 Horseblock Road<br>Medford, NY 11763<br>(Address of principal executive offices) |   |
|   | 631-924-1135<br>(Registrant's Telephone Number)                                       |   |

N/A  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

## Item 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

At the Company's annual stockholder meeting on October 31, 2013, stockholders elected directors of the Company to serve until the next annual meeting of stockholders or until their respective successors are elected and qualified. Stockholders also ratified the selection of BDO USA LLP as the Company's independent registered certified accountants to audit the Company's financial statements as of and for the year ending December 31, 2013, and approved, on an advisory basis, the compensation paid to the Company's named executive officers. The stockholders also approved a one (1) year frequency time period for future advisory votes by stockholders concerning compensation paid to the Company's named executive officers. A tabulation of the matters voted on at this annual stockholder meeting is set forth below.

|   |   |   |   |   |                        |
|---|---|---|---|---|------------------------|
| Proposal #1:– Election of Directors For | Kathy L. Davis  | Barbara D. DeBuono  | Peter Kissinger   | Dr. Gary Meller                         | Lawrence A. Siebert    |
| Withheld/Against                        | 4,102,381   | 3,799,133   | 4,121,993   | 3,983,415                               | 3,980,253              |
| Broker non-votes                        | 31,755  | 155,003   | 12,143  | 150,721                                 | 153,883                |
|   | 3,731,397   | 3,911,397   | 3,731,397   | 3,731,397                               | 3,731,397              |
| Proposal #2-6:                          | Ratifying BDO USA LLP as the Company's Independent Auditors for the year ending December 31, 2013 | Approve Compensation paid to the Company's named Executive Officers | Approve One Year frequency to approve Compensation paid to named Executive Officers | Vote to Adjourn Or Postpone the meeting | Vote on Other Business |
| For                                     | 7,838,094   | 3,494,733   | 2,159,884   | 7,037,329                               | 6,064,543              |
| Withheld/Against                        | 15,775  | 489,260   | 1,886,660   | 735,471                                 | 1,706,183              |
| Abstain                                 | 11,664  | 149,830   | 87,592  | 92,733                                  | 94,807                 |
| Broker non-votes                        | -   | 3,731,710   | 3,731,397   | -                                       | -                      |

## ITEM 7.01. REGULATION FD DISCLOSURE.

On October 31, 2013, the Company issued a press release entitled "Chembio Launches DPP® HIV-Syphilis Test". A copy of the press release is furnished herewith as Exhibit 99.1.

On October 31, 2013, the Company presented a PowerPoint Presentation to the stockholders entitled "Annual Meeting of Shareholders". A copy of the presentation is furnished herewith as Exhibit 99.2A and Exhibit 99.2B.

The information in this Item 7.01 of this Form 8-K is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Form 8-K also shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference.

## ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

Exhibits.

- 99.1 Press Release entitled "Chembio Launches DPP® HIV-Syphilis Test" dated October 31, 2013.
- 99.2A Presentation entitled "Annual Meeting of Shareholders" dated October 31, 2013 (Word version).
- 99.2B Presentation entitled "Annual Meeting of Shareholders" dated October 31, 2013 (PDF version).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 6, 2013

Chembio Diagnostics, Inc.

By: /s/ Lawrence A. Siebert  
Lawrence A. Siebert  
Chief Executive Officer